Rationales, evidence, and design considerations for fractionated radioimmunotherapy

Cancer

Volumn 94, Issue 4 SUPPL., 2002, Pages 1332-1348

  DeNardo, Gerald L ^a,f   Schlom, Jeffery ^b   Buchsbaum, Donald J ^c   Meredith, Ruby F ^c   O'Donoghue, Joseph A ^d,e   Sgouros, George ^d   Humm, John L ^d   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Cancer; Fractionation; Radiation; Radioimmunotherapy; Radioisotope; Radionuclide; Therapy

Indexed keywords

RADIOISOTOPE; EDRECOLOMAB; FERRITIN ANTIBODY; GIRENTUXIMAB I 131; IODINE 131; MONOCLONAL ANTIBODY B.72.3 I 131; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY LYM 1; YTTRIUM 90;

ANIMAL EXPERIMENT; CANCER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; DOSIMETRY; HUMAN; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION BEAM; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RADIOIMMUNOTHERAPY; TREATMENT PLANNING; BONE MARROW TOXICITY; CLINICAL TRIAL (TOPIC); COLON CANCER; COLON CARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HODGKIN DISEASE; INDIVIDUALIZATION; KIDNEY CARCINOMA; LIVER TOXICITY; MORTALITY; NONHODGKIN LYMPHOMA; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; RADIOACTIVITY; RADIOBIOLOGY; RADIOSENSITIVITY; SINGLE DRUG DOSE; TITRIMETRY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 0037083345     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10304     Document Type: Conference Paper

References (108)

1. Radiation biology
2. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoas: First report of RTOG 9003
3. Transmutability of dose and time commentary on the first report of RTOG 90003
4. Confirmation of improved local-regional control with altered fractionation in head and neck cancer
5. The steepness of the dose-response curve in radiation therapy
6. 67Cu-2IT-BAT-Lym-1 radio immunotherapy
7. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation
8. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts
9. The dose-rate effect revisited: Radiobiological considerations of importance in radiotherapy
10. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
11. 131I-Lym-1
12. Low-dose fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody
13. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
14. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions
15. Radioimmuno therapy of lymphoma with fractionated I-131 Lym-1: Phase I/II study
16. Vascular and interstitial barriers to delivery of therapeutic agents in tumors
17. Dosimetric aspects of radiolabeled antibodies for tumor therapy
18. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors
19. An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a "binding site barrier"
20. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: Comparison with experimental data
21. Introduction: Radiolabeled antibody tumor dosimetry
22. 131Iodine-labeled antibody for colon cancer model
23. The implications of nonuniform tumor doses for radioimmunotherapy
24. Radioimmunotherapy
25. Determinants of tumor blood flow: A review
26. The macroscopic and microscopic pharmacology of monoclonal antibodies
27. Tumor architecture and targeted delivery
28. 2H-nuclear magnetic resonance imaging of tumor blood flow: Spacial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma
29. Tumoral vascularity as a prognostic factor in cancer
30. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts
31. Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts
32. Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy
33. Mechanisms of heterogenious distibution of monoclonal antibodies and other macromolecules in turmors; significance of elevated interstitial pressure
34. Time-dependent behavior of interstitial fluid pressure in solid tumors: Implications for drug delivery
35. Oncotic pressure in solid tumors is elevated
36. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse
37. Tumor angiogenesis and interstitial hypertension
38. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier
39. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier
40. Targeting cancer micrometastases with monoclonal antibodies: A binding-site barrier
41. Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy
42. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies
43. A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts
44. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy
45. Fractionated radioimmunotherapy of human colon carcinoma xenografts with I-131-labeled monoclonal antibody CC49
46. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats
47. Hematologic side effects of radiolabeled immunoglobulin therapy
48. Myelosuppressive changes from single or repeated doses of radioantibody therapy: Effect of bone marrow transplantation, cytokines, and hematopoietic suppression
49. Dosimetric aspects of radioimmunotherapy
50. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam
51. 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs
52. Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: Histological and autoradiographic study of effects on tumors and normal organs
53. 131I-labeled CC49 for therapy in a colon cancer xenograft model
54. Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model
55. 186-Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice
56. Suppression of tumor vascular activity by radioantibody therapy: Implications for multiple cycle treatments
57. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability
58. Changes in tumor vascular permeability in response to experimental radioimmunotherapy: A comparative study of 11 xenografts
59. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer
60. 131I-chimeric B72.3 antibody therapy
61. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
62. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential
63. Fractionated radioimmunotherapy with I-131-labeled chimeric antibody G250 (CG250) in patients with metastatic renal cell carcinoma
64. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease
65. Update: Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease
66. Responses of normal tissues to dose fractionation
67. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy
68. A preliminary cell-kinetics model of thrombocytopenia after radioimmunotherapy
69. Dosimetric principles of targeted radiotherapy
70. Time-dose-fractionation in radioimmunotherapy: Implications for selecting radionuclides
71. Radiobiological aspects of low dose rates in radioimmunotherapy
72. Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters
73. Tumor and normal tissue tolerance for fractionated low-dose-rate radiotherapy
74. Dose fractionation, dose-rate and isoeffect relationships for normal tissue responses
75. A new isoeffect curve for changes in dose per fraction
76. A generalised definition of dosimetric quantities
77. Clinical radiobiology of squamous cell carcinoma of the oropharynx
78. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer
79. Loss of local control with prolongation in radiotherapy
80. Planned and unplanned gaps in radiotherapy: The importance of gap position and gap duration
81. Further analysis of radiobiological parameters from the first and second British-Institute-of-Radiology randomized studies of larynx pharynx radiotherapy
82. The adverse effect of treatment prolongation in cervical carcinoma
83. The hazard of accelerated tumor clonogen repopulation during radiotherapy
84. Cell repopulation and overall treatment time
85. The phantom of tumor treatment-continually rapid proliferation unmasked
86. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer
87. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry
88. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice
89. Radiation-induced mitotic delay in L-cells
90. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure
91. Protracted exposure radiosensitization of experimental human malignant glioma
92. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250
93. Distribution of radiolabeled monoclonal antibody MX35 F(ab′)2 in tissue samples by storage phosphor screen image analysis: Evaluation of antibody localization to micrometastatic disease in epthelial ovarian cancer
94. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy
95. Overview of obstacles and opportunities for radioimmunotherapy of cancer
96. Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer
97. Haemodynamic and transport barriers to the treatment of solid tumors
98. Barriers to drug delivery in solid tumors
99. The effect of antigen concentration, antibody valency and size, and tumor architecture on antibody binding in multicell spheroids
100. Yttrium-90 DOTATOC: First clinical results
101. 153Sm-EDTMP using the Vienna protocol
102. CDR substitutions of a humanized monoclonal antibody (CC49): Contributions of individual CDRs to antigen binding and immunogenicity
103. Structural correlates of an anticarcinoma Ab: Identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only
104. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
105. Fractionated radiotherapy
106. Apoptosis and response to radiation: Implications for radiation therapy
107. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model